CMT NEWS
Topline Results from NMD’s Phase 2a Study of Ignaseclant with CMT patients!
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 Exploratory Phase 2a study showed...
TIN-sponsored researcher recognized by Peripheral Nerve Society with prestigious award
Erva Bayraktar, Ph.D. was recently awarded the Peripheral Nerve Society's Laura Feltri Basic Science Fellowship at its annual meeting, held in May in...
Study to Repurpose MS Drug Shows CMT1X Benefit
In a TIN-sponsored study newly published in the May issue of Neuromuscular Disorders (https://doi.org/10.1016/j.nmd.2025.105345) the Martini group now reports...
Seeking Participants for a New CMT Clinical Trial (for the US only) A Chance to Help Advance Treatment
The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible...
Physical Exercise as a possible Therapy for CMT1X
New Physical Exercise study published in November, 2024 issue of the Journal of the Peripheral Nervous SystemThe results of a TIN-sponsored study to determine...
For CMTers Like Me Its Important to Just Keep Moving
For Steve O’Donnell, founder of Therapies for Inherited Neuropathies, those are words to live by. He calls them his life’s slogan. The slogan helps him...
Therapies for Inherited Neuropathies Announces New Addition to the Advisory Board
Mario Bortolozzi, Ph. D. I am an associate Professor in Biophysics at the Department of Physics and Astronomy "G. Galilei" at the University of Padua in...
Therapies for Inherited Neuropathies Announces 2025 TIN CUP for CMT
The TIN CUP for CMT Therapies for Inherited Neuropathies (TIN) is a fully accredited 501(C)3 nonprofit whose sole focus is dedicated to identifying and...
Letter from CMT Patient – Success with Therapy
Email from CMT Patient from June 2023 Hello Mr. O'Donnell, It is a pleasure to be put in touch with you. I am a 39 year old man with 1A who has been working...
TIN team meets key milestone, advances the development of therapeutics antibodies for the treatment of CMT1X.
Therapies for Inherited Neuropathies team meets a key milestone and advances the development of therapeutics antibodies for the treatment of CMT1X. The...